2,3-二氢酞嗪-1,4-二酮二腙单甲烷磺酸盐 | 69467-96-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2,3-二氢酞嗪-1,4-二酮二腙单甲烷磺酸盐
• 英文名称: Dihydralazine mesylate
• 英文别名: (4-hydrazinylphthalazin-1-yl)hydrazine;methanesulfonic acid
• CAS: 69467-96-5
• 化学式: C9H14N6O3S
• 分子量: 286.31
• InChiKey: DRFCWYSGNDFNPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.29
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  165
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• Rottlerin for the treatment of pulmonary hypertension and related diseases and disorders
  申请人：ATB Innovation Ltd.

  公开号：EP2578210A1

  公开（公告）日：2013-04-10

  The inventions discloses a pharmaceutical composition comprising rottlerin or a pharmaceutically acceptable salt thereof or one or more of its derivatives or a pharmaceutically acceptable salt thereof said derivative having the formula wherein X is selected from the group consisting of CH2, O, N, P, and S; R1 and R3 are selected from the group consisting of H, OH, NH2, SH, SO, S-NH-R, NH-R (R selected from the group consisting of alkyl, alkenyl, alkinyl, aryl, phenyl, benzyl, ester, ether, carbonyl, carboxyl, F, Cl, Br, I, H), alkyl, alkenyl, alkinyl, aryl, phenyl, benzyl, ester, ether, carbonyl, carboxyl, F, Cl, Br, I and H; R2 is selected from the group consisting of ethanone, acetyl, alkyl, alkenyl alkinyl, aryl, phenyl, benzyl, ester ether, carbonyl, carboxyl, F, Cl, Br, I and H; R4 is CO-[(E)CHCH]n-Ph, CN-[(E)CHCH]n-Ph, or COOZ, wherein Z is selected from the group consisting of alkenyl, aryl, and alkyl, alkyl, alkenyl, alkinyl, aryl, phenyl, benzyl, ester, ether, carbonyl, carboxyl, F, Cl, Br, I and H; R5, R6, R7 and R8 are selected from the group consisting of methyl, H, P, OH, NH2, SH, SO, S-NH-R, NH-R (R selected from the group consisting of alkyl, alkenyl, alkinyl, aryl, phenyl, benzyl, ester, ether, carbonyl, carboxyl, F, Cl, Br, I, H), alkyl, alkenyl, alkinyl, aryl, phenyl, benzyl, ester, ether, carbonyl, carboxyl, F, Cl, Br, I and H, for use in a method of preventing or treating pulmonary hypertension.

  本发明公开了一种药物组合物，该组合物包含腐霉利或其药学上可接受的盐或其一种或多种衍生物或其药学上可接受的盐，所述衍生物的化学式为 其中 X 选自 CH2、O、N、P 和 S 组成的组；R1 和 R3 选自 H、OH、NH2、SH、SO、S-NH-R、NH-R（R 选自烷基、烯基、烷基、芳基、苯基、苄基、酯、醚、羰基、羧基、F、Cl、Br、I、H 所组成的组）、烷基、烯基、烷基、芳基、苯基、苄基、酯、醚、羰基、羧基、F、Cl、Br、I 和 H；R2 选自乙酮、乙酰基、烷基、烯基烷基、芳基、苯基、苄基、酯、醚、羰基、羧基、 F、Cl、Br、I 和 H 所组成的组；R4 是 CO-[(E)CHCH]n-Ph、CN-[(E)CHCH]n-Ph 或 COOZ，其中 Z 选自由烯基、芳基和烷基、烷基、烯基、烷基、芳基、苯基、苄基、酯、醚、羰基、羧基、F、Cl、Br、I 和 H 组成的组；R5、R6、R7 和 R8 选自由甲基、H、P、OH、NH2、SH、SO、S-NH-R、NH-R （R 选自由烷基、烯基、烷基、芳基、苯基、苄基、酯、醚、羰基、羧基、F、Cl、Br、I 和 H 组成的组）、羰基、羧基、F、Cl、Br、I、H）、烷基、烯基、烷基、芳基、苯基、苄基、酯、醚、羰基、羧基、F、Cl、Br、I 和 H，用于预防或治疗肺动脉高压的方法。
• PHARMAZEUTISCHE DARREICHUNGSFORM
  申请人：Müller, Dieter

  公开号：EP0907388A1

  公开（公告）日：1999-04-14
• CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE
  申请人：Elan Pharma International Limited

  公开号：EP1948135A2

  公开（公告）日：2008-07-30
• Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride
  申请人：Rekhi Singh Gurvinder

  公开号：US20070098796A1

  公开（公告）日：2007-05-03

  The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.
• Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
  申请人：Rekhi Singh Gurvinder

  公开号：US20070098791A1

  公开（公告）日：2007-05-03

  The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.